WW International Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue fell 11% YoY, but Adjusted EBITDA rose 21% and Core+ continued to grow. FY2026 guidance was narrowed, with clinical revenue expected to reach approximately 25% of the mix; management is targeting sustainable profitability in 2027.
-
Debt has been reduced by over 70%, enabling reinvestment in both behavioral and rapidly growing clinical GLP-1 businesses. Technology upgrades, new virtual programs, and partnerships like Sam's Club are driving engagement and revenue diversification, with gross margins and cash flow at sustainable highs.
-
Q2 saw revenue decline year-over-year but strong growth in higher-value Core+ and Clinical segments, driving a 10.2% ARPU increase. Debt was reduced by over 70% from pre-reorganization levels, and full-year guidance for revenue and adjusted EBITDA was reaffirmed.
-
Q1 2026 saw strong growth in clinical and Core+ segments, with clinical revenue up 32% and Core+ subscribers up 6% year-over-year. Revenue declined 10% overall, but ARPU rose 13% and gross margin remained near record highs. 2026 guidance for revenue and adjusted EBITDA was reaffirmed.
-
The company is integrating GLP-1 medications with behavioral support, leveraging financial restructuring to invest in innovation, and expanding its offerings with targeted programs like menopause support. Strategic partnerships and technology upgrades are driving growth and member engagement.
Fiscal Year 2025
-
Exited Chapter 11, eliminated $1.1B in debt, and beat 2025 revenue and EBITDA guidance. Clinical Med+ subscriber growth and ARPU expansion offset behavioral declines, with 2026 revenue guided to $620–$635M and adjusted EBITDA to $105–$115M.
-
Q3 saw revenue decline 11% year over year, but clinical revenue grew 35% and clinical subscribers rose 60%. The company is investing in digital transformation, new product launches, and partnerships, while narrowing 2025 guidance to $695–$700 million in revenue and $145–$150 million in adjusted EBITDA.
-
Debt reduced by over 70% and Q2 revenue reached $189 million, with clinical revenue up 55% but overall subscribers down 17% year-over-year. 2025 guidance calls for $685–$700 million in revenue and $140–$150 million in adjusted EBITDA, with continued investment in clinical and women's health offerings.
-
Debt will be reduced by over 70% to $465 million, halving annual interest payments and strengthening the financial foundation. Q1 revenue declined 10% year-over-year, but clinical revenue grew 57% and clinical subscribers rose 47%. Operations remain uninterrupted during reorganization.
Fiscal Year 2024
-
Q4 2024 revenue declined 10% year-over-year, with behavioral business down but clinical revenue up nearly 60%. Cost actions drove record margins, while high leverage and GLP-1 supply uncertainty remain key risks. 2025 is a reset year focused on stabilization and growth.
-
Q3 revenue declined 6% year-over-year to $193 million, with subscriber count down 9% amid higher acquisition costs and industry disruption. Clinical business showed strong growth and improved retention, while cost-saving initiatives drove record gross margins. Full-year guidance is reiterated, but high leverage and competitive pressures remain challenges.
-
Q2 revenue declined 5% year-over-year to $202M, with subscriber count down 6%, but clinical subscribers surged 120%. Cost actions target $100M in annualized savings, and 2024 guidance includes at least $770M revenue and $100M adjusted operating income.